HC Wainwright Predicts Higher Earnings for BridgeBio Pharma

BridgeBio Pharma, Inc. (NASDAQ:BBIO) – Equities researchers at HC Wainwright upped their Q4 2026 earnings per share estimates for shares of BridgeBio Pharma in a research report issued on Monday, July 13th. HC Wainwright analyst R. Selvaraju now forecasts that the company will earn $0.14 per share for the quarter, up from their prior estimate of $0.12. HC Wainwright currently has a “Buy” rating and a $120.00 target price on the stock. The consensus estimate for BridgeBio Pharma’s current full-year earnings is ($2.30) per share. HC Wainwright also issued estimates for BridgeBio Pharma’s Q2 2027 earnings at $0.44 EPS, Q3 2027 earnings at $0.71 EPS, Q4 2027 earnings at $0.92 EPS and FY2027 earnings at $2.19 EPS.

BridgeBio Pharma (NASDAQ:BBIO) last issued its quarterly earnings data on Thursday, May 7th. The company reported ($0.84) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.70) by ($0.14). The company had revenue of $194.51 million for the quarter, compared to analysts’ expectations of $178.07 million. During the same quarter in the prior year, the business posted ($0.88) EPS. The company’s revenue for the quarter was up 66.8% compared to the same quarter last year.

BBIO has been the topic of several other reports. Raymond James Financial lowered shares of BridgeBio Pharma from an “outperform” rating to a “market perform” rating in a report on Tuesday, May 26th. Royal Bank Of Canada assumed coverage on shares of BridgeBio Pharma in a report on Thursday, April 9th. They issued an “outperform” rating and a $100.00 target price for the company. Mizuho cut their target price on BridgeBio Pharma from $106.00 to $96.00 and set an “outperform” rating on the stock in a research report on Tuesday, June 16th. Truist Financial upped their price target on BridgeBio Pharma from $95.00 to $102.00 and gave the stock a “buy” rating in a research note on Wednesday, April 29th. Finally, Weiss Ratings restated a “sell (d)” rating on shares of BridgeBio Pharma in a research report on Friday, May 15th. Twenty research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $94.63.

BridgeBio Pharma Price Performance

Shares of BBIO opened at $83.08 on Tuesday. BridgeBio Pharma has a 1-year low of $42.09 and a 1-year high of $93.42. The stock has a market cap of $16.27 billion, a PE ratio of -22.21 and a beta of 0.95. The firm has a 50-day simple moving average of $70.00 and a two-hundred day simple moving average of $72.14.

Insider Buying and Selling at BridgeBio Pharma

In related news, CEO Neil Kumar sold 40,000 shares of the company’s stock in a transaction that occurred on Thursday, June 4th. The shares were sold at an average price of $67.46, for a total transaction of $2,698,400.00. Following the sale, the chief executive officer directly owned 535,686 shares of the company’s stock, valued at $36,137,377.56. This represents a 6.95% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Andrea Ellis sold 17,167 shares of the stock in a transaction that occurred on Thursday, July 9th. The stock was sold at an average price of $84.00, for a total transaction of $1,442,028.00. Following the sale, the director owned 22,579 shares in the company, valued at approximately $1,896,636. This trade represents a 43.19% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 432,117 shares of company stock valued at $32,633,740. Corporate insiders own 14.23% of the company’s stock.

Hedge Funds Weigh In On BridgeBio Pharma

Institutional investors have recently modified their holdings of the business. First Bank & Trust increased its position in shares of BridgeBio Pharma by 1.6% during the second quarter. First Bank & Trust now owns 8,797 shares of the company’s stock worth $655,000 after acquiring an additional 142 shares during the period. GAMMA Investing LLC raised its stake in shares of BridgeBio Pharma by 13.8% in the second quarter. GAMMA Investing LLC now owns 1,646 shares of the company’s stock valued at $123,000 after acquiring an additional 199 shares in the last quarter. Harbor Investment Advisory LLC purchased a new position in BridgeBio Pharma in the second quarter valued at $137,000. Parallel Advisors LLC boosted its holdings in BridgeBio Pharma by 552.6% in the first quarter. Parallel Advisors LLC now owns 894 shares of the company’s stock valued at $66,000 after purchasing an additional 757 shares during the period. Finally, Avidity Partners Management LP acquired a new position in BridgeBio Pharma during the 1st quarter worth $711,000. Institutional investors and hedge funds own 99.85% of the company’s stock.

Key Stories Impacting BridgeBio Pharma

Here are the key news stories impacting BridgeBio Pharma this week:

• Positive Sentiment: HC Wainwright raised its price target on BridgeBio Pharma to $120 from $110 and reiterated a buy rating, signaling confidence in further upside. HC Wainwright Raises Price Target on BridgeBio Pharma
• Positive Sentiment: RBC Capital also reaffirmed its buy rating on BBIO, adding to the bullish analyst backdrop. RBC Capital Reaffirms Buy Rating
• Positive Sentiment: Investor commentary highlighted BridgeBio’s strong commercial progress for Attruby and pipeline catalysts, including potential NDA submissions, which could support future revenue growth. BridgeBio Pipeline and Attruby Update
• Positive Sentiment: BridgeBio was also mentioned as a beneficiary of a competitor’s Phase 3 setback, which may have improved sentiment around the company’s relative position in biotech. Biotech Winners and Losers Article
• Neutral Sentiment: Director Jennifer E. Cook sold 148,589 shares, and director Andrea Ellis sold 17,167 shares; both sales were made under pre-arranged 10b5-1 plans, which makes them less concerning than discretionary selling but still worth noting. BridgeBio Insider Selling Alert

BridgeBio Pharma Company Profile

BridgeBio Pharma, Inc is a clinical-stage biopharmaceutical company headquartered in Palo Alto, California. Founded in 2015 by Neil Kumar, the company is dedicated to discovering, developing and delivering transformative medicines for patients with genetic diseases and cancers. BridgeBio operates an integrated model that spans target identification, preclinical research, clinical development and commercialization, aiming to streamline the process from bench to bedside.

BridgeBio’s pipeline comprises multiple therapeutic modalities, including small molecules, biologics and genetic therapies.